Novo Seeds expands company formation activities at BiOrigin with seasoned entrepreneurs

Date: November 26, 2019 Location: Copenhagen Martin Bonde, John Haurum and Anders Hinsby join as Entrepreneurs-in-Residence Peter Hirth and Anders Gersel Pedersen join as Advisors  Novo Seeds, the early stage investment arm of Novo Holdings, wholly owned by the Novo Nordisk Foundation, today announced that its advisory unit, BiOrigin, has appointed several seasoned entrepreneurs to […]

IXICO Notice of Results

IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, will announce its final results for the year ended 30 September 2019 on Wednesday, 4 December 2019. Giulio Cerroni, CEO and Grant Nash, CFO, will host a breakfast briefing and call for analysts at 09:00 GMT on the day of the results.  […]

Azeria Therapeutics announces £32.0 million series B financing

Syncona leads £32.0 million Series B financing of Azeria Therapeutics with a £29.5 million commitment Opportunity to address a significant unmet need in oestrogen receptor positive breast cancer patients in lead programme and to build a world class pioneer factor oncology company  London, 21 November 2019 – Azeria Therapeutics (Azeria), a newly formed pioneer factor […]

Castor Establishes Advisory Board of Industry Leaders to Maximize the Impact of its Clinical Data Platform

Industry veterans including Craig Lipset will support Castor’s vision to advance the future of clinical research Amsterdam, Netherlands and Hoboken, New Jersey:  November 18, 2019: Castor, a health-tech company that aims to leverage machine readable data to increase clinical trial efficiency, today announces the formation of an independent Advisory Board. Castor’s Electronic Data Capture (EDC) […]

Theragnostics strengthens leadership team with two key appointments

Chris Sterling appointed as Non-Executive Director & Radiopharmaceutical drug development expert Dr Daniel Stevens joins as Chief Medical Officer LONDON, UK, 14 November 2019 – Theragnostics, which is developing molecular radiotherapy for imaging and treating a broad range of cancers, announces two strategic hires to its leadership team with the appointment of Dr Daniel Stevens […]

© Optimum Strategic Communications.